ZA200103566B - Pharmaceutical compositions containing poly(ADP-ribose) glycohydrolase inhibitors and methods of using the same. - Google Patents
Pharmaceutical compositions containing poly(ADP-ribose) glycohydrolase inhibitors and methods of using the same. Download PDFInfo
- Publication number
- ZA200103566B ZA200103566B ZA200103566A ZA200103566A ZA200103566B ZA 200103566 B ZA200103566 B ZA 200103566B ZA 200103566 A ZA200103566 A ZA 200103566A ZA 200103566 A ZA200103566 A ZA 200103566A ZA 200103566 B ZA200103566 B ZA 200103566B
- Authority
- ZA
- South Africa
- Prior art keywords
- hydrogen atom
- diseases
- formula
- pharmaceutical composition
- pharmaceutically acceptable
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims description 87
- 102100032347 Poly(ADP-ribose) glycohydrolase Human genes 0.000 title claims description 84
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 32
- 108010078356 poly ADP-ribose glycohydrolase Proteins 0.000 title description 73
- 238000000034 method Methods 0.000 title description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 82
- -1 4-hydroxy-3-methoxybenzoyl Chemical group 0.000 claims description 72
- 201000010099 disease Diseases 0.000 claims description 52
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 44
- 230000000451 tissue damage Effects 0.000 claims description 36
- 231100000827 tissue damage Toxicity 0.000 claims description 36
- 230000030833 cell death Effects 0.000 claims description 34
- 208000035475 disorder Diseases 0.000 claims description 30
- 230000001537 neural effect Effects 0.000 claims description 29
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 28
- 229920005610 lignin Polymers 0.000 claims description 25
- 230000005779 cell damage Effects 0.000 claims description 22
- 230000017074 necrotic cell death Effects 0.000 claims description 22
- 206010040070 Septic Shock Diseases 0.000 claims description 21
- 230000006907 apoptotic process Effects 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 21
- 229930182470 glycoside Natural products 0.000 claims description 21
- 150000002338 glycosides Chemical class 0.000 claims description 21
- 208000006011 Stroke Diseases 0.000 claims description 20
- 208000037887 cell injury Diseases 0.000 claims description 20
- 230000001413 cellular effect Effects 0.000 claims description 20
- 239000002207 metabolite Substances 0.000 claims description 20
- 208000028867 ischemia Diseases 0.000 claims description 19
- 230000001404 mediated effect Effects 0.000 claims description 19
- 150000002148 esters Chemical class 0.000 claims description 18
- 150000004676 glycans Chemical class 0.000 claims description 18
- 229920001282 polysaccharide Polymers 0.000 claims description 18
- 239000005017 polysaccharide Substances 0.000 claims description 18
- 229940002612 prodrug Drugs 0.000 claims description 18
- 239000000651 prodrug Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 18
- 230000002792 vascular Effects 0.000 claims description 18
- 230000004770 neurodegeneration Effects 0.000 claims description 17
- 206010003246 arthritis Diseases 0.000 claims description 16
- 150000003254 radicals Chemical class 0.000 claims description 16
- 206010063837 Reperfusion injury Diseases 0.000 claims description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 208000004296 neuralgia Diseases 0.000 claims description 15
- 208000021722 neuropathic pain Diseases 0.000 claims description 15
- 230000036303 septic shock Effects 0.000 claims description 15
- 210000002027 skeletal muscle Anatomy 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 14
- 208000001132 Osteoporosis Diseases 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 201000008482 osteoarthritis Diseases 0.000 claims description 14
- 230000009759 skin aging Effects 0.000 claims description 14
- 201000001320 Atherosclerosis Diseases 0.000 claims description 13
- 206010019196 Head injury Diseases 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 208000002780 macular degeneration Diseases 0.000 claims description 13
- 201000006938 muscular dystrophy Diseases 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 13
- 206010029216 Nervousness Diseases 0.000 claims description 12
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 12
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 230000002757 inflammatory effect Effects 0.000 claims description 12
- 201000006370 kidney failure Diseases 0.000 claims description 12
- 208000032253 retinal ischemia Diseases 0.000 claims description 12
- 206010006895 Cachexia Diseases 0.000 claims description 11
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 11
- 208000012902 Nervous system disease Diseases 0.000 claims description 9
- 208000025966 Neurological disease Diseases 0.000 claims description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- CTSPAMFJBXKSOY-UHFFFAOYSA-N ellipticine Chemical compound N1=CC=C2C(C)=C(NC=3C4=CC=CC=3)C4=C(C)C2=C1 CTSPAMFJBXKSOY-UHFFFAOYSA-N 0.000 claims description 8
- 229920001461 hydrolysable tannin Polymers 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 229920001864 tannin Polymers 0.000 claims description 8
- 239000001648 tannin Substances 0.000 claims description 8
- 235000018553 tannin Nutrition 0.000 claims description 8
- MPMFCABZENCRHV-UHFFFAOYSA-N tilorone Chemical class C1=C(OCCN(CC)CC)C=C2C(=O)C3=CC(OCCN(CC)CC)=CC=C3C2=C1 MPMFCABZENCRHV-UHFFFAOYSA-N 0.000 claims description 7
- 210000004881 tumor cell Anatomy 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 4
- ZIXGXMMUKPLXBB-UHFFFAOYSA-N Guatambuinine Natural products N1C2=CC=CC=C2C2=C1C(C)=C1C=CN=C(C)C1=C2 ZIXGXMMUKPLXBB-UHFFFAOYSA-N 0.000 claims description 4
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 claims description 4
- SUYXJDLXGFPMCQ-INIZCTEOSA-N SJ000287331 Natural products CC1=c2cnccc2=C(C)C2=Nc3ccccc3[C@H]12 SUYXJDLXGFPMCQ-INIZCTEOSA-N 0.000 claims description 4
- 150000001251 acridines Chemical class 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 229920001968 ellagitannin Polymers 0.000 claims description 4
- 229920002824 gallotannin Polymers 0.000 claims description 4
- 150000002303 glucose derivatives Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229960000286 proflavine Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 230000000637 radiosensitizating effect Effects 0.000 claims description 3
- 101000589450 Homo sapiens Poly(ADP-ribose) glycohydrolase Proteins 0.000 claims 12
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 7
- QJYNZEYHSMRWBK-NIKIMHBISA-N 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose Chemical compound OC1=C(O)C(O)=CC(C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(O)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(O)C(O)=C(O)C=2)=C1 QJYNZEYHSMRWBK-NIKIMHBISA-N 0.000 claims 4
- 230000006806 disease prevention Effects 0.000 claims 3
- YKAWWEJYQJFUDE-YNHSGPELSA-N 1-[(3R,4S,5S,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxan-2-yl]-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one Chemical compound COC=1C=C(C=CC(=O)C2(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O2)CO)C=C(C=1OC)OC YKAWWEJYQJFUDE-YNHSGPELSA-N 0.000 claims 1
- GQHBDCVPWLVGRD-OLGSFBKRSA-N COc1cc(C=CC(=O)OC[C@H]2OC(OC(=O)C=Cc3cc(OC)c(O)c(OC)c3)[C@H](OC(=O)C=Cc3cc(OC)c(O)c(OC)c3)[C@@H](OC(=O)C=Cc3cc(OC)c(O)c(OC)c3)[C@@H]2OC(=O)C=Cc2cc(OC)c(O)c(OC)c2)cc(OC)c1O Chemical compound COc1cc(C=CC(=O)OC[C@H]2OC(OC(=O)C=Cc3cc(OC)c(O)c(OC)c3)[C@H](OC(=O)C=Cc3cc(OC)c(O)c(OC)c3)[C@@H](OC(=O)C=Cc3cc(OC)c(O)c(OC)c3)[C@@H]2OC(=O)C=Cc2cc(OC)c(O)c(OC)c2)cc(OC)c1O GQHBDCVPWLVGRD-OLGSFBKRSA-N 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 93
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 92
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 88
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 48
- 230000000694 effects Effects 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 32
- 239000012661 PARP inhibitor Substances 0.000 description 27
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 27
- 108091026813 Poly(ADPribose) Proteins 0.000 description 27
- 230000004913 activation Effects 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 18
- 206010029350 Neurotoxicity Diseases 0.000 description 18
- 206010044221 Toxic encephalopathy Diseases 0.000 description 18
- 231100000228 neurotoxicity Toxicity 0.000 description 18
- 230000007135 neurotoxicity Effects 0.000 description 18
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 16
- 229930195712 glutamate Natural products 0.000 description 16
- 230000005778 DNA damage Effects 0.000 description 15
- 231100000277 DNA damage Toxicity 0.000 description 15
- 102000003960 Ligases Human genes 0.000 description 13
- 108090000364 Ligases Proteins 0.000 description 13
- 206010028851 Necrosis Diseases 0.000 description 13
- 239000011575 calcium Substances 0.000 description 13
- 230000006378 damage Effects 0.000 description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- 230000002222 downregulating effect Effects 0.000 description 12
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 11
- 230000033616 DNA repair Effects 0.000 description 10
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 230000009758 senescence Effects 0.000 description 8
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 230000001054 cortical effect Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 229950006238 nadide Drugs 0.000 description 7
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 230000005731 poly ADP ribosylation Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 6
- 206010014824 Endotoxic shock Diseases 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 6
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 6
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 206010009887 colitis Diseases 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000004165 myocardium Anatomy 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000005730 ADP ribosylation Effects 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000010094 cellular senescence Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 4
- 231100001074 DNA strand break Toxicity 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 4
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 4
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 4
- 102000007999 Nuclear Proteins Human genes 0.000 description 4
- 108010089610 Nuclear Proteins Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000003835 adenosine derivatives Chemical class 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010093894 Xanthine oxidase Proteins 0.000 description 3
- GCWPGEWXYDEQAY-NKWVEPMBSA-N [(1r,2r)-2-aminocyclohexyl]methanol Chemical compound N[C@@H]1CCCC[C@H]1CO GCWPGEWXYDEQAY-NKWVEPMBSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 208000005298 acute pain Diseases 0.000 description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 230000002964 excitative effect Effects 0.000 description 3
- 230000003492 excitotoxic effect Effects 0.000 description 3
- 231100000063 excitotoxicity Toxicity 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 231100000189 neurotoxic Toxicity 0.000 description 3
- 230000002887 neurotoxic effect Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 230000008943 replicative senescence Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 229950006823 tilorone Drugs 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 2
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 2
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 2
- 230000007035 DNA breakage Effects 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000018899 Glutamate Receptors Human genes 0.000 description 2
- 108010027915 Glutamate Receptors Proteins 0.000 description 2
- 102100034228 Grainyhead-like protein 1 homolog Human genes 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000019439 energy homeostasis Effects 0.000 description 2
- 230000036566 epidermal hyperplasia Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- LFUJIPVWTMGYDG-UHFFFAOYSA-N isoquinoline-1,5-diol Chemical compound N1=CC=C2C(O)=CC=CC2=C1O LFUJIPVWTMGYDG-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 231100000188 sister chromatid exchange Toxicity 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- VQWHLMLLUNSUMV-UHFFFAOYSA-N 1-hydroxy-2-methylpyrrolidine-2,3-diol phosphono dihydrogen phosphate Chemical compound CC1(O)C(O)CCN1O.OP(O)(=O)OP(O)(O)=O VQWHLMLLUNSUMV-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- WWRAFPGUBABZSD-UHFFFAOYSA-N 6-amino-5-iodochromen-2-one Chemical compound O1C(=O)C=CC2=C(I)C(N)=CC=C21 WWRAFPGUBABZSD-UHFFFAOYSA-N 0.000 description 1
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- SRNWOUGRCWSEMX-TYASJMOZSA-N ADP-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1OC(O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-TYASJMOZSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 102100033195 DNA ligase 4 Human genes 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 208000017452 Epidermal disease Diseases 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150101566 Parp gene Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 229940123066 Polymerase inhibitor Drugs 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- NDQDTBCXPOIQGT-UHNJQBFTSA-N [(2R,3R,4S)-3,4-dihydroxypyrrolidin-2-yl]methyl-ADP Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1NC[C@H](O)[C@@H]1O NDQDTBCXPOIQGT-UHNJQBFTSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000033590 base-excision repair Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 230000007726 cellular glucose metabolism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000000782 cerebellar granule cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 108091006090 chromatin-associated proteins Proteins 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000004046 hyporesponsiveness Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000012022 methylating agents Substances 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000020520 nucleotide-excision repair Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- RZFVLEJOHSLEFR-UHFFFAOYSA-N phenanthridone Chemical compound C1=CC=C2C(O)=NC3=CC=CC=C3C2=C1 RZFVLEJOHSLEFR-UHFFFAOYSA-N 0.000 description 1
- NLNIWCUPDREYCA-VEGRVEBRSA-N phosphono dihydrogen phosphate;(2r,3r,4r)-2,3,4,5-tetrahydroxypentanal Chemical compound OP(O)(=O)OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@@H](O)C=O NLNIWCUPDREYCA-VEGRVEBRSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical class CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000003363 transsynaptic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/182,645 US20030078212A1 (en) | 1998-10-30 | 1998-10-30 | Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200103566B true ZA200103566B (en) | 2002-12-03 |
Family
ID=22669416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200103566A ZA200103566B (en) | 1998-10-30 | 2001-05-03 | Pharmaceutical compositions containing poly(ADP-ribose) glycohydrolase inhibitors and methods of using the same. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20030078212A1 (zh) |
EP (1) | EP1171130A4 (zh) |
JP (1) | JP2002540060A (zh) |
KR (1) | KR20010113632A (zh) |
CN (1) | CN1367693A (zh) |
AU (1) | AU777503B2 (zh) |
BR (1) | BR9914878A (zh) |
CA (1) | CA2350052A1 (zh) |
CZ (1) | CZ20011389A3 (zh) |
HK (1) | HK1041595A1 (zh) |
HU (1) | HUP0300886A2 (zh) |
IL (1) | IL142770A0 (zh) |
MX (1) | MXPA01004340A (zh) |
NO (1) | NO20011950L (zh) |
PL (1) | PL356063A1 (zh) |
WO (1) | WO2000025787A1 (zh) |
ZA (1) | ZA200103566B (zh) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6585716B2 (en) * | 2000-04-05 | 2003-07-01 | Biocardia, Inc. | Method of treating the heart |
US7838046B2 (en) * | 2001-09-26 | 2010-11-23 | Tampa Bay Research Institute | Plant extracts and uses thereof |
US6866875B2 (en) * | 2001-09-26 | 2005-03-15 | Tampa Bay Research Institute | Pine cone extracts and uses thereof |
AU2002322623A1 (en) * | 2002-07-24 | 2004-02-09 | Ohio University | Methods and compositions for treating diabetes mellitis |
US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
US7176188B2 (en) * | 2003-05-07 | 2007-02-13 | UniversitéLaval | Method of lethally sensitizing human and animal cells |
EP1636376A2 (en) * | 2003-06-13 | 2006-03-22 | The Babraham Institute | Differential gene expression in schizophrenia |
CA2529510A1 (en) * | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
US20060025337A1 (en) * | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
EP1708689A2 (en) | 2003-12-29 | 2006-10-11 | The President and Fellows of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
AU2005262472B2 (en) * | 2004-06-16 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for modulating bax-mediated apoptosis |
US20060014705A1 (en) * | 2004-06-30 | 2006-01-19 | Howitz Konrad T | Compositions and methods for selectively activating human sirtuins |
WO2006138418A2 (en) * | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
WO2007064795A2 (en) * | 2005-11-30 | 2007-06-07 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
JP2007223974A (ja) * | 2006-02-24 | 2007-09-06 | Japan Health Science Foundation | ポリ(adp−リボース)グリコヒドロラーゼ分解耐性のポリ(エテノadp−リボース) |
US8734867B2 (en) * | 2007-12-28 | 2014-05-27 | Liveleaf, Inc. | Antibacterial having an extract of pomegranate combined with hydrogen peroxide |
SG10201502453SA (en) | 2009-03-04 | 2015-05-28 | Liveleaf Inc | Method and material for site activated complexing of biologic molecules |
WO2011085454A1 (en) * | 2010-01-18 | 2011-07-21 | Katholieke Universiteit Leuven K.U.Leuven R&D | Gp120 -binding benzene compounds and saccharide compounds |
SG10201602286RA (en) | 2010-12-23 | 2016-04-28 | Amazentis Sa | Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders |
US8722040B2 (en) | 2011-06-24 | 2014-05-13 | Liveleaf, Inc. | Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites |
US9192635B2 (en) | 2011-06-24 | 2015-11-24 | Liveleaf, Inc. | Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide |
US8883857B2 (en) | 2012-12-07 | 2014-11-11 | Baylor College Of Medicine | Small molecule xanthine oxidase inhibitors and methods of use |
US8716351B1 (en) | 2012-12-23 | 2014-05-06 | Liveleaf, Inc. | Methods of treating gastrointestinal spasms |
US10155738B2 (en) | 2014-04-04 | 2018-12-18 | University Of Rhode Island | Methods for skin whitening using a gallotannin |
WO2015178791A1 (ru) * | 2014-05-23 | 2015-11-26 | Артур Викторович МАРТЫНОВ | Косметологическая и фармацевтическая композиция |
WO2015183121A1 (ru) * | 2014-05-26 | 2015-12-03 | Общество с ограниченной ответственностью "Уникат" | Устройство нагрева локальных участков трубопровода |
JP2020510678A (ja) | 2017-03-08 | 2020-04-09 | アマゼンティス エスアーAmazentis Sa | 対象におけるマイトファジーを改善するための方法 |
CN109125337B (zh) * | 2018-07-23 | 2021-06-22 | 澳门科技大学 | 赶黄草化合物在制备治疗动脉粥样硬化的药物中的应用 |
CN110448563A (zh) * | 2019-07-19 | 2019-11-15 | 南京中医药大学 | 1,2,3,4,6-五没食子酰葡萄糖在制备防治骨质疏松症药品中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0103878B1 (de) * | 1982-09-17 | 1990-12-27 | Humán Oltoanyagtermelö és Kutato Intézet | Präparate zur Behandlung von Wunden der Hautoberfläche und Verfahren zur Herstellung derartiger Präparate |
JPH0759515B2 (ja) * | 1986-10-21 | 1995-06-28 | 株式会社ツムラ | アルド−スリダクタ−ゼ阻害剤 |
JP2784605B2 (ja) * | 1990-04-28 | 1998-08-06 | 靖一 田沼 | リグニン配糖体およびその用途 |
JP3067233B2 (ja) * | 1991-03-04 | 2000-07-17 | ウェルファイド株式会社 | アデノシン誘導体およびその用途 |
JP3185802B2 (ja) * | 1991-03-04 | 2001-07-11 | ウェルファイド株式会社 | ポリ(adp−リボース)グリコヒドロラーゼ阻害剤 |
US5587384A (en) * | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
DE4415087A1 (de) * | 1994-04-29 | 1995-11-09 | Zschiegner Hans Joachim Dr | Mittel als Wirkstoffe bzw. Wirkstoffgemische zur Anwendung in der Balneotherapie, Gesundheitspflege und Kosmetik und Verfahren zur Herstellung pharmazeutischer Erzeugnisse sowie Verfahren zu ihrer Anwendung |
US6110902A (en) * | 1997-06-23 | 2000-08-29 | Moehler; Hanns | Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine |
WO1999011644A1 (en) * | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
-
1998
- 1998-10-30 US US09/182,645 patent/US20030078212A1/en not_active Abandoned
-
1999
- 1999-11-01 IL IL14277099A patent/IL142770A0/xx unknown
- 1999-11-01 CA CA002350052A patent/CA2350052A1/en not_active Abandoned
- 1999-11-01 WO PCT/US1999/025521 patent/WO2000025787A1/en not_active Application Discontinuation
- 1999-11-01 AU AU13325/00A patent/AU777503B2/en not_active Ceased
- 1999-11-01 MX MXPA01004340A patent/MXPA01004340A/es unknown
- 1999-11-01 JP JP2000579228A patent/JP2002540060A/ja active Pending
- 1999-11-01 BR BR9914878-1A patent/BR9914878A/pt not_active IP Right Cessation
- 1999-11-01 CN CN99816808A patent/CN1367693A/zh active Pending
- 1999-11-01 HU HU0300886A patent/HUP0300886A2/hu unknown
- 1999-11-01 KR KR1020017005357A patent/KR20010113632A/ko not_active Application Discontinuation
- 1999-11-01 EP EP99956794A patent/EP1171130A4/en not_active Withdrawn
- 1999-11-01 CZ CZ20011389A patent/CZ20011389A3/cs unknown
- 1999-11-01 PL PL99356063A patent/PL356063A1/xx not_active Application Discontinuation
-
2001
- 2001-04-19 NO NO20011950A patent/NO20011950L/no not_active Application Discontinuation
- 2001-05-03 ZA ZA200103566A patent/ZA200103566B/en unknown
-
2002
- 2002-04-27 HK HK02103160.6A patent/HK1041595A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0300886A2 (hu) | 2003-07-28 |
CN1367693A (zh) | 2002-09-04 |
CA2350052A1 (en) | 2000-05-11 |
HK1041595A1 (zh) | 2002-07-12 |
AU777503B2 (en) | 2004-10-21 |
CZ20011389A3 (cs) | 2001-09-12 |
JP2002540060A (ja) | 2002-11-26 |
PL356063A1 (en) | 2004-06-14 |
NO20011950L (no) | 2001-06-25 |
KR20010113632A (ko) | 2001-12-28 |
BR9914878A (pt) | 2003-01-07 |
AU1332500A (en) | 2000-05-22 |
MXPA01004340A (es) | 2003-06-06 |
EP1171130A4 (en) | 2004-05-19 |
US20030078212A1 (en) | 2003-04-24 |
IL142770A0 (en) | 2002-03-10 |
EP1171130A1 (en) | 2002-01-16 |
NO20011950D0 (no) | 2001-04-19 |
WO2000025787A1 (en) | 2000-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200103566B (en) | Pharmaceutical compositions containing poly(ADP-ribose) glycohydrolase inhibitors and methods of using the same. | |
Curtin | PARP inhibitors for cancer therapy | |
Heeres et al. | Poly (ADP-ribose) makes a date with death | |
de La Lastra et al. | Poly (ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications | |
EP1339402B1 (en) | Azaphenanthridone derivatives and their use as parp inhibitors | |
EP1649017B1 (en) | Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer | |
US6723733B2 (en) | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses | |
Cosi | New inhibitors of poly (ADP-ribose) polymerase and their potential therapeutic targets | |
Beneke et al. | Poly (ADP‐ribosyl) ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions | |
US7750008B2 (en) | Compounds, methods and pharmaceutical compositions for inhibiting PARP | |
Cepeda et al. | Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy | |
TWI338000B (en) | Dna damage repair inhibitors for treatment of cancer | |
NL1025842C2 (nl) | Zouten van tricyclische remmers van poly (ADP-ribose) polymerasen. | |
ZA200200830B (en) | Tricyclic inhibitors of poly(ADP-ribose) polymerases. | |
JP2002515490A (ja) | Parp活性を抑制する縮合三環化合物 | |
Woon et al. | Poly (ADP-ribose) polymerase inhibition-where now? | |
JP4787409B2 (ja) | 治療用ホスホジエステラーゼ阻害剤 | |
Komjáti et al. | Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma | |
US6537973B1 (en) | Oligonucleotide inhibition of protein kinase C | |
WO1999011644A1 (en) | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity | |
Skaper | Poly (ADP-ribosyl) ation enzyme-1 as a target for neuroprotection in acute central nervous system injury | |
Zhang et al. | PARP and PARG as novel therapeutic targets | |
WO2003004606A2 (en) | Antisense oligonucleotides and related methods for regulating cell death | |
Rouleau et al. | Potential role of PARP inhibitors in cancer treatment and cell death | |
Pommier | DNA TOP2: ENZYMOLOGY AND CELL BIOLOGY TOP2 POISONS TOP2 SUPPRESSORS CONCLUSIONS |